With a vaccine directed against endogenous retroviruses, the progression of tumour growth could be significantly inhibited in a mouse model. The prophylactic vaccination could even prevent the development of tumours. The results of this research project were reported in the online edition of PLoS ONE dated 30 August 2013 (11 p.m. CET).
The murine renal carcinoma cell line Renca. On the left: without HERV-K envelope protein expression. On the right: genetically modified Renca cells with HERV-K envelope protein (in red).
Source: PEI - The image is available with 300 dpi (4,7x13,7 cm) - please ask the PEI Press and information office
Human endogenous retroviruses (HERV) entered the human genome millions of years ago and have been passed on from generation to generation. The human genome contains several thousand such endogenous retrovirus genes. As a rule, the genes of HERV are mute, i.e. they do not produce proteins. Researchers of the Paul-Ehrlich-Institut and other groups have already been able to show that an increase in expression of genes of one group of these retroviruses occurs in HIV infected individuals but also in the tumour cells of various types of cancer. The HERV group could be identified as HERV-K/HML-2(hom), or for short, HERV-K. Professor Dr Barbara Schnierle and her co-workers in the Virology Division of the Paul-Ehrlich-Institut now wanted to know whether the specific gene activity of HERV-K could be used therapeutically to fight cancer cells in a targeted manner. To protect healthy cells, it is required to identify structures as targets which are only displayed on cancer cells.
For their investigations, Professor Barbara Schnierle, head of the Section "AIDS, New and Emerging Pathogens", and her co-workers used a murine kidney cell line (Renca). This cell line had been genetically modified in such a way that the cells produced (human) HERV-K envelope proteins to emulate the situation of the HERV-positive human cancer cells as accurately as possible. Mice which received an i.v. administration of these cells developed lung metastases within a short period of time.
For the "vaccination" against these tumours, the researchers used the modified vaccinia virus Ankara (MVA), an attenuated virus which cannot replicate after inoculation. In addition, Professor Schnierle and her co-workers had inserted the gene for the HERV-K envelope protein into the MVA genome. After the inoculation, the gene is read in the cells and the envelope protein is formed. It is presented to the immune system as antigen and an immune response can be induced.
Then the PEI scientists performed investigations to establish whether their "vaccine" could be used both for therapeutic and for prophylactic purposes: For the therapeutic approach, they first injected the genetically modified mouse cancer cells, then waited ten days until lung metastases were formed and then treated part of the mice with the MVA vaccine. The tumours grew considerably more slowly in the vaccinated animals and fewer metastases were observed than in the non-vaccinated animals. However, complete tumour remission was not achieved.
With regard to the prophylactic vaccination, the effect was even more significant: Here, the animals were at first vaccinated twice with the virus (days 0 and 21), and the cancer cells were administered twelve days later. The animals thus vaccinated were protected entirely from tumour development – no metastases could be identified.
"The findings have shown for the first time that the HERV-K envelope protein could be a useful target for the development of a vaccine, and may be able to provide new options for the treatment of various tumours" explained Professor Schnierle.
The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines in Langen in the federal state of Hessen, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute. The PEI, with its roughly 800 staff, also has advisory functions at a national level (federal government, federal states (Länder)), and at an international level (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0072756 Publication (Fulltext)http://www.pei.de/EN/information/journalists-press/press-releases/2013/04-prehistoric-relics-targets-vaccination-against-cancer.html
Press Release on the PEI-Website
Dr. Susanne Stöcker | idw
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences